Trademarkia Logo

Canada

C$
XTINDUBEC
REGISTERED

on 28 Jun 2024

Last Applicant/ Owned by

CELGENE CORPORATION

Route 206 & Province Line RoadPrinceton, NJ 08543

US

Serial Number

2064556 filed on 17th Nov 2020

Registration Number

TMA1240857 registered on 28th Jun 2024

Registration expiry Date

28th Jun 2034

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

XTINDUBEC

Trademark usage description

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence,cardiovascular diseases, heart failure, thrombosis Read More

Classification Information


Class [005]
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence,cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immunediseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis,fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis,leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiplesclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations forhuman use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity,hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely,antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, centralnervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs;pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer,respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplantrejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as antiinfectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use forincreasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations forhuman use that modulate the immune system; pharmaceutical preparations for human use, namely,immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies;pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceuticalpreparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use;Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease,and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals fortreatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders;pharmaceutical preparations for human use namely monoclonal antibodies


Classification kind code

11

Mark Details


Serial Number

2064556

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 42
on 10th Apr 2024
Advertised
Submitted for opposition 135
on 21st Mar 2024
Amendment to Application
Submitted for opposition 26
on 15th Mar 2024
Approved
Submitted for opposition 27
on 15th Mar 2024
Approval Notice Sent
Submitted for opposition 22
on 12th Apr 2023
Search Recorded
Submitted for opposition 20
on 12th Apr 2023
Examiner's First Report
Submitted for opposition 287
on 20th Oct 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 17th Nov 2020
Filed
Submitted for opposition 1
on 17th Nov 2020
Created
Submitted for opposition 31
on 17th Nov 2020
Formalized